Literature DB >> 6429940

Haemorrhagic tumour necrosis following endotoxin administration. I. Communication: morphological investigation on endotoxin-induced necrosis of the methylcholanthrene (Meth A) tumour in the mouse.

N Freudenberg, K Joh, O Westphal, C Mittermayer, M A Freudenberg, C Galanos.   

Abstract

Endotoxin induced necrosis of the Meth A mouse tumour has been investigated using macroscopic, histological and ultrastructural examination methods. On the 8th day after tumour cell transplantation, the animals received a relatively non-toxic dose of the Salmonella abortus equi endotoxin intravenously. The natural history of the tumour necrosis took the following course: The earliest morphological changes could be seen with the electron microscope 90 min after administration of the endotoxin, and were seen as an interstitial oedema with separation of the tumour cells. Haemorrhagic necrosis of the tumour was complete 4 hours after injection, and could be easily recognized with the naked eye. Rejection of the necrotic malignant tumour was complete two weeks after LPS administration. Only minor residual scarring of the belly-wall remained. Haemorrhagic tumour necrosis due to endotoxin can be compared with the localized Shwartzman reaction and probably involves tumour necrotizing factor (TNF). For complete destruction of a tumour by haemorrhagic necrosis the size of the tumour is critical. Certain regression after endotoxin administration depends upon additional T-cell-mediated immunity (provided the tumour is immunogenic). In contrast to the haemorrhagic necrosis, BCG-induced tumour regression is accompanied by granulomatous inflammation, which may be responsible for destruction of the tumour.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6429940     DOI: 10.1007/bf00737287

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  17 in total

1.  Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse.

Authors:  L J OLD; D A CLARKE; B BENACERRAF
Journal:  Nature       Date:  1959-07-25       Impact factor: 49.962

2.  Mixed bacterial toxins in the treatment of tumors. II. Gross and microscopic changes produced in sarcoma 37 and in mouse tissues.

Authors:  A J DONNELLY; H F HAVAS; M E GROESBECK
Journal:  Cancer Res       Date:  1958-02       Impact factor: 12.701

3.  The role of the reticuloendothelial system in the host reaction to neoplasia.

Authors:  L J OLD; B BENACERRAF; D A CLARKE; E A CARSWELL; E STOCKERT
Journal:  Cancer Res       Date:  1961-10       Impact factor: 12.701

4.  A new method for the extraction of R lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1969-06

5.  Preparation and properties of a standardized lipopolysaccharide from salmonella abortus equi (Novo-Pyrexal).

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Zentralbl Bakteriol Orig A       Date:  1979-04

6.  Effect of endotoxin on tumor resistance in mice.

Authors:  C Yang; A Nowotny
Journal:  Infect Immun       Date:  1974-01       Impact factor: 3.441

7.  Partial purification of a serum factor that causes necrosis of tumors.

Authors:  S Green; A Dobrjansky; E A Carswell; R L Kassel; L J Old; N Fiore; M K Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1976-02       Impact factor: 11.205

8.  Inhibitory effect of endotoxin on the growth of plasma cell tumor.

Authors:  L A Bober; M J Kranepool; V P Hollander
Journal:  Cancer Res       Date:  1976-03       Impact factor: 12.701

9.  Requirement for a radiosensitive lymphoid cell in the generation of lipopolysaccharide-induced rejection of a murine tumor allograft.

Authors:  M J Berendt; G F Mezrow; P H Saluk
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

10.  Studies on the heterologous immunogenicity of a methanol-insoluble fraction of attenuated tubercle bacilli (BCG). II. Protection against tumor isografts.

Authors:  D W Weiss; R S Bonhag; P Leslie
Journal:  J Exp Med       Date:  1966-12-01       Impact factor: 14.307

View more
  4 in total

1.  Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents.

Authors:  J S Patton; P M Peters; J McCabe; D Crase; S Hansen; A B Chen; D Liggitt
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

2.  Tumor necrosis factor alpha and lymphotoxin production in Hodgkin's disease.

Authors:  C Kretschmer; D B Jones; K Morrison; C Schlüter; W Feist; A J Ulmer; J Arnoldi; J Matthes; T Diamantstein; H D Flad
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

3.  Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.

Authors:  T Yamazaki; D Hannani; V Poirier-Colame; S Ladoire; C Locher; A Sistigu; N Prada; S Adjemian; J P P Catani; M Freudenberg; C Galanos; F André; G Kroemer; L Zitvogel
Journal:  Cell Death Differ       Date:  2013-06-28       Impact factor: 15.828

4.  Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells.

Authors:  M A Schwarz; J Kandel; J Brett; J Li; J Hayward; R E Schwarz; O Chappey; J L Wautier; J Chabot; P Lo Gerfo; D Stern
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.